Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jacalyn Mara Rosenblatt, M.D.

Title
Institution
Department
Address
Phone

Mentoring
Available: 04/05/22, Expires: 06/01/23

Our group has developed a personalized tumor vaccine whereby patient derived tumor cells are fused to ex-vivo generated dendritic cells. We are conducting clinical trials in AML and multiple myeloma and assessing immune and clinical response to vaccination. Pre-clinical studies focus on novel combination therapy and exploration of novel biomarkers


Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA262629 (AVIGAN, DAVID E) Jul 1, 2021 - Jun 30, 2026
    NIH
    Personalized Adoptive T-cell Therapy for AML
    Role: Co-Principal Investigator
  2. R21CA149987 (ROSENBLATT, JACALYN) Apr 1, 2010 - Mar 31, 2013
    NIH
    Dendritic Cell/Leukemia Fusions and PD-1 Blockade for AML
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sklavenitis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, Usmani SZ, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Mateos MV, Trippa L, Getz G, Ghobrial IM. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8. PMID: 36379208; PMCID: PMC10019228.
    Citations: 1     Fields:    Translation:Humans
  2. Laubach JP, Tuchman SA, Rosenblatt JM, Mitsiades CS, Colson K, Masone K, Warren D, Redd RA, Grayson D, Richardson PG. Phase 1 open-label study of panobinostat, lenalidomide, bortezomib?+?dexamethasone in relapsed and relapsed/refractory multiple myeloma. Blood Cancer J. 2021 02 05; 11(2):20. PMID: 33563894.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  3. Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC, Elemento O, Novak J, Thornley TB, Asara JM, Montaser L, Timmons JJ, Morgan TM, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP, Cantley LC. Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discov. 2017 07; 7(7):750-765. PMID: 28274958; PMCID: PMC5501767.
    Citations: 65     Fields:    Translation:HumansAnimalsCells
  4. Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171. PMID: 27928025; PMCID: PMC5800949.
    Citations: 78     Fields:    Translation:HumansCellsPHPublic Health
  5. Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, Raje N, Boussiotis V, Yuan YE, Bisharat L, Held V, Rowe J, Anderson K, Kufe D, Avigan D. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8. PMID: 23685836.
    Citations: 91     Fields:    Translation:HumansCellsPHPublic Health
  6. Vasir B, Zarwan C, Ahmad R, Crawford KD, Rajabi H, Matsuoka K, Rosenblatt J, Wu Z, Mills H, Kufe D, Avigan D. Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC). J Immunother. 2012 Sep; 35(7):555-69. PMID: 22892452.
    Citations: 6     Fields:    Translation:HumansCells
  7. Tan CS, Bord E, Broge TA, Glotzbecker B, Mills H, Gheuens S, Rosenblatt J, Avigan D, Koralnik IJ. Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):244-8. PMID: 22549384; PMCID: PMC3400136.
    Citations: 34     Fields:    Translation:HumansCells
  8. Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, Joyce RM, Levine JD, Anderson KC, Kufe D, Avigan D. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013 Jan; 62(1):39-49. PMID: 22733396.
    Citations: 82     Fields:    Translation:HumansCells
  9. Avigan D, Rosenblatt J, Kufe D. Dendritic/tumor fusion cells as cancer vaccines. Semin Oncol. 2012 Jun; 39(3):287-95. PMID: 22595051.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  10. Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7. PMID: 21991938.
    Citations: 2     Fields:    Translation:Humans
  11. Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16. PMID: 21975917.
    Citations: 12     Fields:    Translation:Humans
  12. Rosenblatt J, McDermott DF. Immunotherapy for renal cell carcinoma. Hematol Oncol Clin North Am. 2011 Aug; 25(4):793-812. PMID: 21763968.
    Citations: 12     Fields:    Translation:Humans
  13. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, Rotem-Yehudar R, Kufe D, Avigan D. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun; 34(5):409-18. PMID: 21577144.
    Citations: 150     Fields:    Translation:HumansCells
  14. Yin L, Wu Z, Avigan D, Rosenblatt J, Stone R, Kharbanda S, Kufe D. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood. 2011 May 05; 117(18):4863-70. PMID: 21422470; PMCID: PMC3100696.
    Citations: 23     Fields:    Translation:HumansCells
  15. Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402. PMID: 21030562; PMCID: PMC3031474.
    Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
  16. Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother. 2010 Feb-Mar; 33(2):155-66. PMID: 20145548.
    Citations: 15     Fields:    Translation:HumansCells
  17. Rosenblatt J, Bissonnette A, Ahmad R, Wu Z, Vasir B, Stevenson K, Zarwan C, Keefe W, Glotzbecker B, Mills H, Joyce R, Levine JD, Tzachanis D, Boussiotis V, Kufe D, Avigan D. Immunomodulatory effects of vitamin D: implications for GVHD. Bone Marrow Transplant. 2010 Sep; 45(9):1463-8. PMID: 20081878.
    Citations: 15     Fields:    Translation:HumansCells
  18. Rosenblatt J, Avigan D. Cellular immunotherapy for multiple myeloma. Best Pract Res Clin Haematol. 2008 Sep; 21(3):559-77. PMID: 18790455.
    Citations: 10     Fields:    Translation:Humans
  19. Vasir B, Wu Z, Crawford K, Rosenblatt J, Zarwan C, Bissonnette A, Kufe D, Avigan D. Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J Immunol. 2008 Jul 01; 181(1):808-21. PMID: 18566447; PMCID: PMC2938172.
    Citations: 19     Fields:    Translation:HumansCells
  20. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, Pandolfi PP. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008 Jun 19; 453(7198):1072-8. PMID: 18469801.
    Citations: 249     Fields:    Translation:HumansAnimalsCells
  21. Kawano T, Ito M, Raina D, Wu Z, Rosenblatt J, Avigan D, Stone R, Kufe D. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res. 2007 Dec 15; 67(24):11576-84. PMID: 18089786.
    Citations: 20     Fields:    Translation:HumansCells
  22. Rosenblatt J, Avigan D. Can leukemia-derived dendritic cells generate antileukemia immunity? Expert Rev Vaccines. 2006 Aug; 5(4):467-72. PMID: 16989627.
    Citations: 5     Fields:    Translation:HumansCells
  23. Vasir B, Borges V, Wu Z, Grosman D, Rosenblatt J, Irie M, Anderson K, Kufe D, Avigan D. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol. 2005 Jun; 129(5):687-700. PMID: 15916692.
    Citations: 17     Fields:    Translation:HumansCells
  24. Rosenblatt J, Kufe D, Avigan D. Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opin Biol Ther. 2005 May; 5(5):703-15. PMID: 15934845.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  25. Cunningham ST, Rosenblatt JS, Komisaruk BR. Reflexive ovulation in the rat, induced by caesarean section, is blocked by pelvic and/or hypogastric nerve transection. Neuroendocrinology. 1992 Sep; 56(3):393-6. PMID: 1436377.
    Citations:    Fields:    Translation:Animals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Rosenblatt's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (173)
Explore
_
Co-Authors (43)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.